Comparing the Biological Activity and Composition of Cerebrolysin with Other Peptide Preparations

Overview

Journal J Med Life

Specialty General Medicine

Date 2024 May 13

PMID 38737662

Authors

Lisa-Franziska Seidl

Ludwig Aigner

Affiliations

Soon will be listed here.

Abstract

Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurodegenerative diseases like dementia, are the leading cause of disability-adjusted life years (DALYs) worldwide. A promising approach to address these conditions and promote nervous system regeneration is the use of the neuropeptide preparation Cerebrolysin, which has been shown to be effective in both clinical and preclinical studies. Despite claims of similar clinical efficacy and safety by several peptide preparations, concerns regarding their generic composition and efficacy have been previously raised. Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases. Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.

References

Muresanu D, Florian S, Homberg V, Matula C, von Steinbuchel N, Vos P . Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020; 41(5):1171-1181. DOI: 10.1007/s10072-019-04181-y. View

Bornstein N, Guekht A, Vester J, Heiss W, Gusev E, Homberg V . Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2017; 39(4):629-640. PMC: 5884916. DOI: 10.1007/s10072-017-3214-0. View

Strilciuc S, Vecsei L, Boering D, Praznikar A, Kaut O, Riederer P . Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials. Pharmaceuticals (Basel). 2021; 14(12). PMC: 8708612. DOI: 10.3390/ph14121297. View

Rocco M, Soligo M, Manni L, Aloe L . Nerve Growth Factor: Early Studies and Recent Clinical Trials. Curr Neuropharmacol. 2018; 16(10):1455-1465. PMC: 6295934. DOI: 10.2174/1570159X16666180412092859. View

Guekht A, Vester J, Heiss W, Gusev E, Hoemberg V, Rahlfs V . Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017; 38(10):1761-1769. PMC: 5605586. DOI: 10.1007/s10072-017-3037-z. View

Yeo X, Cunliffe G, Ho R, Lee S, Jung S . Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases. Biomedicines. 2022; 10(2). PMC: 8961788. DOI: 10.3390/biomedicines10020343. View

Muresanu D, Ciurea A, Gorgan R, Gheorghita E, Florian S, Stan H . A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets. 2015; 14(5):587-99. DOI: 10.2174/1871527314666150430162531. View

Poon W, Matula C, Vos P, Muresanu D, von Steinbuchel N, von Wild K . Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2019; 41(2):281-293. DOI: 10.1007/s10072-019-04053-5. View

Huang E, Reichardt L . Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001; 24:677-736. PMC: 2758233. DOI: 10.1146/annurev.neuro.24.1.677. View

10.

Seidl L, Winter S, Aigner L, Schartner J . A Neurofilament-L reporter cell line for the quantification of early neuronal differentiation: A Bioassay for neurotrophic activities. Heliyon. 2024; 10(2):e24753. PMC: 10831791. DOI: 10.1016/j.heliyon.2024.e24753. View

11.

Ouaamari Y, Van den Bos J, Willekens B, Cools N, Wens I . Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives. Int J Mol Sci. 2023; 24(4). PMC: 9968045. DOI: 10.3390/ijms24043866. View

12.

Zhang L, Chopp M, Wang C, Zhang Y, Lu M, Zhang T . Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke. J Neurol Sci. 2019; 398:22-26. DOI: 10.1016/j.jns.2019.01.017. View

13.

Teng H, Li C, Zhang Y, Lu M, Chopp M, Zhang Z . Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. 2021; 32(5):359-366. DOI: 10.1097/WNR.0000000000001598. View

14.

Vester J, Buzoianu A, Florian S, Homberg V, Kim S, Lee T . Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021; 42(11):4531-4541. DOI: 10.1007/s10072-020-04974-6. View

15.

. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5):459-480. PMC: 6459001. DOI: 10.1016/S1474-4422(18)30499-X. View